SEATTLE, April 8, 2008 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced that it has completed the previously announced registered direct offering of 8.0 million shares of its common stock and warrants to purchase up to 8.0 million shares of its common stock. Net proceeds received by Dendreon were approximately $46 million. Lazard Capital Markets LLC served as sole placement agent for the offering.
The offering is being made pursuant to previously effective shelf registration statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the SEC’s website at http://www.sec.gov or from Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY, 10020.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.
Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, market demand for Dendreon’s common stock and events and developments affecting Dendreon’s business and prospects. Information on the factors and risks that could affect Dendreon’s business, financial condition and results of operations are contained in Dendreon’s public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.
CONTACT: Jennifer Cook Williams, Investor Relations of Dendreon
Corporation, +1-206-829-1500
Web site: http://www.dendreon.com/